8-K: Envoy Medical Extends Meteora Shortfall Warrants to 2026

Envoy Medical, Inc. has extended the expiration date of 1.13 million outstanding Shortfall Warrants held by Meteora Parties from December 31, 2025, to December 31, 2026.

Summary

• Envoy Medical, Inc. (the "Company") entered into Amendment No. 4 to Common Stock Purchase Warrant with the Meteora Parties on December 18, 2025.
• The amendment extends the expiration date of 1,125,499 outstanding Shortfall Warrants from December 31, 2025, to December 31, 2026.
• The exercise price of these Shortfall Warrants is determined by a volume-weighted average price (VWAP) formula, measured weekly, subject to a minimum price of $1.50 per share.
• The issuance and resale of shares of Class A Common Stock upon exercise of these warrants were registered under the Company's Form S-3, declared effective on August 12, 2025.
• The Original Warrant was issued on November 27, 2023, for up to 3,874,394 shares of Common Stock and had previous amendments on June 24, 2024, December 19, 2024, and July 28, 2025.
• The amendment confirms that no changes to the Forward Purchase Agreement are necessary to effect these terms, and the adjusted exercise price from the July 29, 2024, amendment remains in effect.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While it defers potential capital, it also avoids the immediate expiration of warrants, maintaining a future option for capital infusion and showing continued engagement with a significant investor. It's a routine financial management action rather than a major operational event.

Positives

• The extension provides the Meteora Parties with additional time (one year) to exercise their Shortfall Warrants, offering flexibility.
• It defers the immediate expiration of a significant number of warrants, maintaining the potential for future capital infusion if exercised.
• The continued existence of these warrants could be seen as a sign of ongoing engagement with a key institutional investor group.

Negatives

• The extension defers potential dilution for existing shareholders, but also delays the potential capital raise that would occur upon exercise.
• The continued overhang of these warrants could create uncertainty regarding future share count and potential dilution.

Risks

• Potential future dilution for existing shareholders if the 1,125,499 Shortfall Warrants are exercised.
• Market price volatility could impact the attractiveness of exercising the warrants, as the exercise price is tied to a VWAP formula with a minimum of $1.50 per share.
• The Company's ability to raise capital through warrant exercises is dependent on its stock performance relative to the $1.50 minimum exercise price and VWAP.

Future Outlook

The extension of the Shortfall Warrants provides the Meteora Parties with an additional year to potentially exercise their warrants, which could result in future capital for Envoy Medical, Inc. and corresponding dilution for existing shareholders. The Company will continue to monitor its stock price relative to the warrant exercise terms.

Management Comments

• "Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized." Brent Lucas, Chief Executive Officer of Envoy Medical, Inc.

Industry Context

Warrant extensions are a common mechanism in corporate finance, particularly for companies that have utilized warrant-based financing. Such extensions can provide flexibility to both the warrant holder and the issuer, allowing more time for market conditions to become favorable for exercise or for the company to achieve milestones that enhance its stock value. This specific amendment reflects ongoing financial management and investor relations with key institutional holders.

Related Party Transactions

• The amendment involves the Meteora Parties (Meteora Special Opportunity Fund I, LP, Meteora Capital Partners, LP, Meteora Select Trading Opportunities Master, LP, and Meteora Strategic Capital, LLC), which are significant institutional investors and warrant holders of Envoy Medical, Inc. This constitutes a dealing with a key stakeholder group.

Stakeholder Impact

• **Shareholders:** Face potential future dilution if the warrants are exercised, but the extension provides more time for the company's value to grow before such dilution occurs. The continued overhang of warrants could also create some uncertainty.
• **Warrant Holders (Meteora Parties):** Benefit from an extended period to exercise their warrants, providing more flexibility to capitalize on potential future stock price appreciation.

Next Steps

• The Meteora Parties will have until December 31, 2026, to decide on the exercise of their 1,125,499 Shortfall Warrants.
• Envoy Medical, Inc. will continue to monitor its stock price and market conditions, which will influence the exercise decisions of the warrant holders.

Key Dates

Recommendation

This filing primarily concerns a contractual amendment to existing warrants, extending their expiration date. While it defers potential dilution and capital infusion, it does not provide new information on the company's operational performance, strategic direction, or financial health that would warrant a change in investment thesis. The extension itself is a neutral to slightly positive event, offering flexibility to both the company and the warrant holders. Therefore, a 'hold' recommendation is appropriate, pending further operational or financial updates.

Keywords

Envoy Medical, Warrant Extension, Meteora, Shortfall Warrants, Common Stock, SEC Filing, Capital Structure, Dilution, VWAP, COCH